Last reviewed · How we verify
Toviaz (Fesoterodine)
Fesoterodine is a muscarinic M3 receptor antagonist that relaxes bladder smooth muscle to reduce urinary incontinence and overactive bladder symptoms.
Fesoterodine is a muscarinic M3 receptor antagonist that relaxes bladder smooth muscle to reduce urinary incontinence and overactive bladder symptoms. Used for Overactive bladder with symptoms of urge incontinence, urgency, and frequency.
At a glance
| Generic name | Toviaz (Fesoterodine) |
|---|---|
| Also known as | Toviaz |
| Sponsor | Weill Medical College of Cornell University |
| Drug class | Muscarinic M3 receptor antagonist |
| Target | M3 muscarinic acetylcholine receptor |
| Modality | Small molecule |
| Therapeutic area | Urology |
| Phase | FDA-approved |
Mechanism of action
Fesoterodine blocks M3 muscarinic acetylcholine receptors on the detrusor muscle of the bladder, preventing involuntary contractions. This anticholinergic action increases bladder capacity and reduces the urge to urinate, thereby decreasing episodes of urgency incontinence and frequency. The drug is a prodrug that is rapidly hydrolyzed to its active metabolite.
Approved indications
- Overactive bladder with symptoms of urge incontinence, urgency, and frequency
Common side effects
- Dry mouth
- Constipation
- Headache
- Urinary retention
- Blurred vision
Key clinical trials
- Deprescribing dRrugs for Overactive Bladder in General Practice (DROP) (NA)
- Efficacy of Low-Intensity Shockwave Therapy in Treating Radiation Cystitis (EARLY_PHASE1)
- Treatment Persistence Among Patients With Overactive Bladder: A Retrospective Secondary Data Analysis in Asia Oceania
- A Prospective, Observational, Multicenter Study of Patients Following Initiation of a New Course of Treatment for Overactive Bladder (OAB)
- Fall Prevention in Older Adults With OAB (PHASE4)
- Inflammation in Women With Urgency Urinary Incontinence Treated With Anticholinergics (PHASE4)
- Drug Use Investigation for Toviaz
- BIOEQUIVALENCE STUDY IN HEALTHY PARTICIPANTS COMPARING 4 MG AND 8 MG FESOTERODINE EXTENDED-RELEASE TABLETS (TOVIAZ™), MANUFACTURED AT ZWICKAU VERSUS FREIBURG (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Toviaz (Fesoterodine) CI brief — competitive landscape report
- Toviaz (Fesoterodine) updates RSS · CI watch RSS
- Weill Medical College of Cornell University portfolio CI